Key result
Applying demographic and case-mix-based weights to commercial insurance data successfully generated nationally representative population estimates, predicting 6,709,438 annual statin users.
Why the study?
National projections from large-scale patient longitudinal databases require adjustment for demographic and health status differences to ensure representativeness.
Observational (n=14,032,320)
Objective: To create a nationally-representative estimate from longitudinal data by controlling for sociodemographic factors and health status. Method: The Agency for Healthcare Research and Quality’s (AHRQ) Medicare Expenditures Panel Survey (MEPS) was used as the basis for adjustment methodology. MEPS is a data source representing health insurance coverage cost and utilization, and comprises several large-scale surveys of families, individuals, employers, and health care providers. Using these data, we created subset populations. We then used multivariate logistic regression to construct demographics and case-mix-based weights, which were applied to create a population sample that is similar to the national population. The weight was derived using the inverse probability of the weighting approach, as well as a raking mechanism. We compared the results with the projected number of persons in the US population in the same categories to examine the validity of the weights. Results: The following variables were used in the logistic regression: Age group, gender, race, location, income level and health status (Charlson Comorbidity Index scores and chronic condition diagnosis). Relative to MEPS data, patients included in the private insurance data were more likely to be male, older, to have a chronic condition, and to be white (p=0.0000). Adjusted weighted values for patients in the commercial group ranged from 15.47 to 36.36 (median: 16.91). Commercial insurance and MEPS data populations were similar in terms of their socioeconomic and clinical categories. As an outcomes measure, the predicted annual number of patients with prescription claims from private insurance data was 6 963 034. The annual number of statin users were predicted as 6 709 438 using weighted MEPS data. Conclusion: National projections of large-scale patient longitudinal databases require adjustment utilizing demographic factors and case-mix differences related to health status.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2016) reported an observational. Statistical weighting (raking and inverse probability weighting) vs. Unweighted commercial data was evaluated on Projected number of people in the US population and annual statin users. Applying demographic and case-mix-based weights to commercial insurance data successfully generated nationally representative population estimates, predicting 6,709,438 annual statin users.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: